Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...
The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...
Moderna Inc. closed $129.71 short of its 52-week high ($170.47), which the company achieved on May 24th.
Igor Kirillov, head of Russia's nuclear and chemical defense, helped spread false claims about Ukraine, the U.S. and COVID-19 ...
It’s likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results